This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marsit, C. J. Articles by Kelsey, K. T. Search for Related Content PubMed PubMed Citation Articles by Marsit, C. J. Articles by Kelsey, K. T.

Epigenetic Inactivation of SFRP Genes and TP53 Alteration Act Jointly as Markers of Invasive Bladder Cancer

Departments of ¹ Genetics and Complex Diseases and ² Environmental Health, Harvard School of Public Health, Boston, Massachusetts; Departments of ³ Community and Family Medicine and ⁴ Pathology, Dartmouth Medical School, Lebanon, New Hamsphire

Requests for reprints: Karl T. Kelsey, Department of Genetics and Complex Diseases, Harvard School of Public Health, 665 Huntington Avenue, Room 607, Building I, Boston, MA 02115. Phone: 617-432-3313; Fax: 617-432-0107; E-mail: kelsey{at}hsph.harvard.edu.

In the United States each year, almost 13,000 deaths are attributable to bladder cancer, with the majority of these deaths related to higher stage, muscle-invasive solid tumors. Epigenetic silencing of the secreted frizzled receptor proteins (SFRP), antagonists of the WNT pathway, leads to constitutive WNT signaling, altering cell morphology and motility. Identifying alterations in this pathway in bladder cancer may prove useful for defining the invasive phenotype and provide targets for guiding therapy. Using a population-based study of bladder cancer (n = 355), we examined epigenetic alterations, specifically gene promoter hypermethylation, of four SFRP genes in addition to immunohistochemical staining of TP53, which has been previously shown to be a predictor of invasive disease. We observed a significant linear trend (P < 0.0004) in the magnitude of the risk of invasive disease with the number of SFRP genes methylated. Both TP53 alteration and SFRP gene methylation showed significant independent associations with invasive bladder cancer. Strikingly, in examining the joint effect of these alterations, we observed a >30-fold risk of invasive disease for patients with both altered SFRP gene methylation and intense TP53 staining (odds ratio, 32.1; P < 10^–13). Overall patient survival was significantly poorer in patients with any SFRP genes methylated (P < 0.0003) and in proportional hazards modeling, patients with methylation of any SFRP gene had significantly poorer overall survival (hazard ratio, 1.78; P < 0.02) controlled for TP53 staining intensity and other survival-associated factors. Classifying tumors based on SFRP methylation status and TP53 protein staining intensity may be a clinically powerful predictor of invasive, deadly disease.

This article has been cited by other articles:

				Y. Tang, A. R. Simoneau, W.-x. Liao, G. Yi, C. Hope, F. Liu, S. Li, J. Xie, R. F. Holcombe, F. A. Jurnak, et al. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells Mol. Cancer Ther., February 1, 2009; 8(2): 458 - 468. [Abstract] [Full Text] [PDF]

				B. C. Christensen, J. J. Godleski, C. J. Marsit, E. A. Houseman, C. Y. Lopez-Fagundo, J. L. Longacker, R. Bueno, D. J. Sugarbaker, H. H. Nelson, and K. T. Kelsey Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma Carcinogenesis, August 1, 2008; 29(8): 1555 - 1559. [Abstract] [Full Text] [PDF]

				J. Veeck, C. Geisler, E. Noetzel, S. Alkaya, A. Hartmann, R. Knuchel, and E. Dahl Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis Carcinogenesis, May 1, 2008; 29(5): 991 - 998. [Abstract] [Full Text] [PDF]

				M. Suzuki, H. Shigematsu, T. Nakajima, R. Kubo, S. Motohashi, Y. Sekine, K. Shibuya, T. Iizasa, K. Hiroshima, Y. Nakatani, et al. Synchronous Alterations of Wnt and Epidermal Growth Factor Receptor Signaling Pathways through Aberrant Methylation and Mutation in Non Small Cell Lung Cancer Clin. Cancer Res., October 15, 2007; 13(20): 6087 - 6092. [Abstract] [Full Text] [PDF]

				C. J. Marsit, E. A. Houseman, A. R. Schned, M. R. Karagas, and K. T. Kelsey Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer Carcinogenesis, August 1, 2007; 28(8): 1745 - 1751. [Abstract] [Full Text] [PDF]

				C. J. Marsit, E. A. Houseman, B. C. Christensen, K. Eddy, R. Bueno, D. J. Sugarbaker, H. H. Nelson, M. R. Karagas, and K. T. Kelsey Examination of a CpG Island Methylator Phenotype and Implications of Methylation Profiles in Solid Tumors Cancer Res., November 1, 2006; 66(21): 10621 - 10629. [Abstract] [Full Text] [PDF]

				S. Urakami, H. Shiina, H. Enokida, T. Kawakami, K. Kawamoto, H. Hirata, Y. Tanaka, N. Kikuno, M. Nakagawa, M. Igawa, et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2109 - 2116. [Abstract] [Full Text] [PDF]